Search all trials

Find therapies in clinical trials near you – page 9

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

HER2 positive breast cancer

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Trastuzumab, Tucatinib, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tucatinib

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Breast cancer

Not recruiting

Registered drug

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Breast cancer+1

Not recruiting

Registered drugNo placebo

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Coronary artery dissection

Not recruiting

Registered drugNo placebo

Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atenolol

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Sacituzumab Govitecan for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Resistant to Hormone and CDK4/6 Inhibitors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Sacituzumab Govitecan

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Registered drugNo placebo

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Anastrozole

Contact Research Centre

Neoplasm malignant

Not recruiting

Registered drug

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

InvestigationalNo placebo

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan

Contact Research Centre

Renal cell carcinoma

Not recruiting

Registered drug

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Fallopian tube cancer+1

Not recruiting

Registered drugNo placebo

Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

InvestigationalNo placebo

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Find therapies in clinical trials near you – page 9

111 trials match your criteria

HER2 positive breast cancer

Study on the Effectiveness and Safety of Trastuzumab, Tucatinib, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

HER2 positive breast cancer

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Breast cancer

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Breast cancer+1

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Coronary artery dissection

Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection

Hormone receptor positive HER2 negative breast cancer

Study on Sacituzumab Govitecan for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Resistant to Hormone and CDK4/6 Inhibitors

Hormone receptor positive breast cancer+1

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Neoplasm malignant

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

Renal cell carcinoma

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Fallopian tube cancer+1

Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

Breast cancer metastatic+1

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.